New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVesugen vs Triptorelin

Vesugen vs Triptorelin

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Vesugen
Sexual Health & Libido
Triptorelin
Summary
Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) with 100x the potency of native GnRH. An FDA-approved drug (Trelstar) for prostate cancer and precocious puberty, it is also used in post-cycle therapy (PCT) to rapidly restart the hypothalamic-pituitary-gonadal (HPG) axis after anabolic steroid suppression.
Half-Life
Short (minutes); sustained gene-regulatory effects
Depot forms: weeks to months; aqueous: 6-8 hours
Admin Route
SubQ, Oral
SubQ, IM
Research
Typical Dose
10 mg per day
100 mcg
Frequency
Daily for 10–30 days
Single injection
Key Benefits
  • Supports vascular endothelial cell function and integrity
  • May reduce endothelial inflammation and dysfunction
  • Anti-aging effects on blood vessel walls
  • Potential benefits in early atherosclerosis and vascular aging
  • Supports nitric oxide-mediated vascular tone
  • Reduces endothelial apoptosis from oxidative stress
  • Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
  • Rapid HPG axis restart after steroid use
  • Single-injection PCT protocol possible
  • Massively elevates LH and FSH via flare effect
  • Restores endogenous testosterone faster than traditional PCT
  • FDA-approved for established medical uses
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant vascular adverse events reported at standard doses
  • Initial testosterone flare (intended)
  • Injection site reactions
  • Hot flashes (with chronic use)
  • Decreased libido (chronic dosing)
Stacks With